{"id":13952,"date":"2025-01-06T13:33:27","date_gmt":"2025-01-06T21:33:27","guid":{"rendered":"https:\/\/depts.washington.edu\/diabetes\/?p=13952"},"modified":"2025-01-06T13:33:27","modified_gmt":"2025-01-06T21:33:27","slug":"zepbound-poised-to-drive-health-care-costs-in-2025","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/diabetes\/zepbound-poised-to-drive-health-care-costs-in-2025\/","title":{"rendered":"Zepbound poised to drive health care costs in 2025"},"content":{"rendered":"<section class=\"kc-elm kc-css-602175 kc_row\"><div class=\"kc-row-container  kc-container\"><div class=\"kc-wrap-columns\"><div class=\"kc-elm kc-css-914143 kc_col-sm-12 kc_column kc_col-sm-12\"><div class=\"kc-col-container\"><div class=\"kc-elm kc-css-199171 kc_text_block\"><p>Eli Lilly&#8217;s anti-obesity drug Zepbound is expected to be a major cost driver for health insurers, government health programs and employers this year, according to Aon and GlobalData. The drug has shown superior efficacy in weight loss compared with Novo Nordisk&#8217;s Wegovy, suggesting it will dominate this market and potentially lead to higher health care premiums, as cost increases are projected for employer-sponsored coverage.<\/p>\n<p>Full Story: <a href=\"https:\/\/www.forbes.com\/sites\/brucejapsen\/2025\/01\/01\/lillys-obesity-drug-zepbound-to-be-key-health-cost-driver-for-2025\/\">Forbes (tiered subscription model)<\/a> (1\/1)\u00a0\u00a0<\/p>\n<div>\u00a0<\/div>\n<div>\u00a0<\/div>\n<div>\u00a0<\/div>\n<div>\u00a0<\/div>\n<\/div><\/div><\/div><\/div><\/div><\/section><!-- \/wp:post-content -->","protected":false},"excerpt":{"rendered":"","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mi_skip_tracking":false,"footnotes":""},"categories":[17],"tags":[],"class_list":["post-13952","post","type-post","status-publish","format-standard","hentry","category-diabetes-related-news"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/posts\/13952","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/comments?post=13952"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/posts\/13952\/revisions"}],"predecessor-version":[{"id":13954,"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/posts\/13952\/revisions\/13954"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/media?parent=13952"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/categories?post=13952"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/tags?post=13952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}